Cowen’s healthcare analyst Phil Nadeau came out with some commentary on Sarepta Therapeutics Inc (NASDAQ:SRPT), after the company released its second-quarter results and provided update on its …
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three and six months ended June 30, 2015, and …
On August 2, Roth Capital analyst Debjit Chattopadhyay published a report providing a list of upcoming catalysts for several biotechnology companies including Sarepta Therapeutics Inc (NASDAQ:SRPT), Bluebird Bio Inc (NASDAQ:BLUE), and Agios …
On August 2, Roth Capital analyst Debjit Chattopadhyay published a report providing a list of upcoming catalysts for several biotechnology companies including Sarepta Therapeutics Inc (NASDAQ:SRPT),Bluebird Bio Inc (NASDAQ:BLUE), and Agios Pharmaceuticals …
Wall Street is in the heart of earnings season with three key biotechnology stocks slated to announce their quarterly financial results this week. …
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, granted equity awards on July 31, 2015, that were previously approved by the Compensation …
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, announced the publication of results from a multiple ascending dose study to determine the …
Roth Capital analyst Debjit Chattopadhyay was out pounding the table on Sarepta Therapeutics Inc (NASDAQ:SRPT) Monday, reiterating a Buy rating and price target of $45, …
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, announced Henri Termeer, industry leader and former CEO of Genzyme, will be a key …
Oppenheimer analyst Christopher Marai came out with a research report on Sarepta Therapeutics Inc (NASDAQ:SRPT) after the company completed its rolling NDA for eteplirsen, a trial …
